irinotecan has been researched along with Bone Marrow Diseases in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adachi, M; Hirose, T; Kusumoto, S; Nakamura, A; Ohmori, T; Shirai, T; Sugiyama, T; Yashiki, C | 1 |
| Hashimoto, S; Kado, S; Kaneda, N; Kurita, A; Onoue, M; Yokokura, T | 1 |
| Du, J; Feng, G; He, L; Li, X; Qin, S; Wang, L; Xing, Q; Xu, L; Xu, M; Yu, L; Zhang, A | 1 |
| Buitenhuis, M; Catimel, G; Dirix, LY; Mathieu-Boué, A; Siegenthaler, P; Verdonk, HE; Verweij, J; Wagener, DJ | 1 |
| Abigerges, D; Armand, JP; Bugat, R; Catimel, G; Chabot, GG; Culine, S; de Forni, M; Extra, JM; Hérait, P; Mahjoubi, M | 1 |
| Calleja, E; Cosetti, M; Gerald, W; Gorlick, R; Healey, JH; Huvos, AG; LaQuaglia, M; Meyers, PA; Trippett, T; Wexler, LH | 1 |
| Asami, K; Kaneko, M; Kishimoto, T; Matsunaga, T; Mimaya, J; Mugishima, H; Sawada, T; Suita, S; Tsuchida, Y; Yagi, K | 1 |
| Bruckner, HW; Kozuch, P; Petryk, M | 1 |
2 review(s) available for irinotecan and Bone Marrow Diseases
| Article | Year |
|---|---|
Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Bone Neoplasms; Camptothecin; Child; Child, Preschool; Diarrhea; Drug Evaluation; Enzyme Inhibitors; Female; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neuroectodermal Tumors, Primitive; New York City; Osteosarcoma; Retrospective Studies; Rhabdomyosarcoma; Sarcoma, Ewing; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Recombinant Proteins; Respiratory Distress Syndrome; Taxoids; Treatment Outcome | 2002 |
3 trial(s) available for irinotecan and Bone Marrow Diseases
| Article | Year |
|---|---|
Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Camptothecin; Disease-Free Survival; Female; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Remission Induction; Topoisomerase I Inhibitors; Treatment Outcome | 1995 |
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
Topics: Adult; Aged; Bone Marrow Diseases; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Half-Life; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Prodrugs; Treatment Outcome | 1995 |
Phase I study of irinotecan in pediatric patients with malignant solid tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Camptothecin; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Irinotecan; Japan; Leiomyosarcoma; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Neoplasm Proteins; Neuroblastoma; Neuroectodermal Tumors, Primitive; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
3 other study(ies) available for irinotecan and Bone Marrow Diseases
| Article | Year |
|---|---|
[Chemotherapy-induced myelosuppression and treatment efficacy in limited-stage disease small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Etoposide; Female; Granulocyte Precursor Cells; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2010 |
Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.
Topics: Algorithms; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Bile; Biotransformation; Blood Cell Count; Body Weight; Bone Marrow; Bone Marrow Diseases; Camptothecin; Diarrhea; Infusions, Intravenous; Intestines; Irinotecan; Male; Rats; Rats, Sprague-Dawley | 2003 |
Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations.
Topics: Adult; Antineoplastic Agents, Phytogenic; Asian People; Bilirubin; Bone Marrow Diseases; Camptothecin; China; Ethnicity; Exons; Female; Gastrointestinal Diseases; Gene Frequency; Genetic Predisposition to Disease; Glucuronosyltransferase; Haplotypes; Heterozygote; Homozygote; Humans; Hyperbilirubinemia; Irinotecan; Linkage Disequilibrium; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Reference Values; TATA Box | 2007 |